RxDoctor Payments DataLook up a doctor →

Vijaya Samuel, MD

Internal Medicine · Overland Park, KSNPI 1104810803

Payments from drug & device makers

$7,504in general payments, 2019–2025

Across 492 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$854
  • Amgen$782
  • Novo Nordisk$753
  • Lilly USA, LLC$534
  • Abbott$365
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,489100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,504 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$181,524
Medicare patients
296
Services billed
3,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$47,197
OzempicSemaglutide22$20,546
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$12,692
RybelsusSemaglutide12$9,861
LinzessLinaclotide11$9,761
VascepaIcosapent Ethyl11$3,839
Losartan Potassium412$3,728
Rosuvastatin Calcium404$3,220
Celecoxib55$2,720
Levothyroxine Sodium286$2,713
Gabapentin195$2,707
Estradiol19$2,206
Atorvastatin Calcium241$1,909
SynthroidLevothyroxine Sodium15$1,894
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$854$47,19739 claims
Novo NordiskOzempic, Rybelsus$753$30,40734 claims
GSKAnoro Ellipta$112$12,69223 claims
AbbVieLinzess, Synthroid$1,437$11,65526 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$2,713286 claims
Sanofi-aventis U.S. LLCLantus$27$89315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →